Matchpoint Raises $150 Million to Advance Oral T-Cell Modulator MPT-062

Matchpoint Therapeutics plans to advance MPT-062, an oral first-in-class T-cell modulator, into clinical development in 2027 for autoimmune and inflammatory diseases. The program is intended to address disease-driving T-cell overactivation through a precision covalent small-molecule approach.

MPT-062 Targets T-Cell Overactivation

MPT-062 is an oral small molecule that Matchpoint is developing to modulate T-cell activity in immune-mediated inflammatory diseases. The company describes the program as first-in-class, with a mechanism intended to selectively address excessive T-cell activation associated with autoimmune disease.

T cells are essential components of the immune system, but persistent or dysregulated activation can contribute to tissue inflammation and disease progression across multiple autoimmune and inflammatory conditions. Oral therapies that can selectively modulate disease-relevant immune pathways could provide an alternative to existing treatment approaches, which include biologics and other systemic immunomodulators.

Matchpoint has not yet reported human clinical efficacy or safety data for MPT-062. The program remains in preclinical development, making its transition into human testing the next major development milestone.

Precision Covalent Approach Supports Drug Discovery

MPT-062 forms part of Matchpoint’s broader precision covalent drug discovery platform. The company combines chemical biology, covalent chemistry, structure-based drug design, and computational sciences to identify small molecules against biologically validated targets that have historically been difficult to address with conventional approaches.

The company is applying this platform to develop oral medicines for autoimmune and inflammatory diseases. Its pipeline includes additional discovery-stage programs, including a program being advanced with funding from Novartis under a collaboration established in July 2025.

Clinical Development Planned for 2027

Matchpoint expects to begin clinical development of MPT-062 in 2027, with the program progressing toward clinical proof-of-concept.

The initial clinical studies will be important for establishing the compound’s safety, tolerability, pharmacologic activity, and potential therapeutic effect in patients. At this stage, the company has not disclosed clinical trial design, target indication, patient population, dose levels, or planned endpoints.

The absence of human data means that the therapeutic potential of MPT-062 remains unvalidated clinically. Early clinical results will therefore be critical in determining whether its T-cell modulation strategy can translate into meaningful disease control.

Matchpoint Raises $150 Million to Support Clinical Progression

The planned clinical development follows the closing of a $150 million Series B financing, which will provide capital for MPT-062 and the company’s broader pipeline.

The financing was co-led by Nextech Invest and Norwest, with participation from new investors Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth. Existing investors, including Access Biotechnology, Atlas Venture, Sanofi Ventures, Digitalis Ventures, and other current backers, also participated.

As part of the financing, Kanishka Pothula, Ph.D., Managing Partner at Nextech Invest, and Brian Matesic, M.D., Principal at Norwest, will join Matchpoint’s Board of Directors.

Matchpoint CEO Andre Turenne said the financing will support advancement of MPT-062 into clinical development while allowing the company to continue progressing additional programs.

The financing gives Matchpoint resources to move its lead program from preclinical development into human studies. The planned 2027 clinical start and subsequent safety and pharmacologic data will be the key milestones for assessing whether MPT-062 can demonstrate proof-of-concept in autoimmune and inflammatory disease.

Reference

Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases, Matchpoint Therapeutics, 07 October 2026